Private Trust Company’s Vanda Pharmaceuticals VNDA Stock Holding History

Private Trust Company’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-20	Closed	–	–	2375
2022 Q4	$0	Buy	+20	New	+$195	﹤0.01%	2279

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Private Trust Company's VNDA Position: Q1 2023 in Review

Private Trust Company sold out of Vanda Pharmaceuticals (VNDA) in Q1 2023, closing a stake of 20 shares.

Private Trust Company first reported a position in VNDA in Q4 2022 and held it in 1 quarter. The position peaked at $0 in Q4 2022. 177 funds tracked by Wall St. Rank hold VNDA as of Q1 2023.

Private Trust Company reported no remaining Vanda Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Private Trust Company sold 20 Vanda Pharmaceuticals shares in Q1 2023.
Private Trust Company first reported a position in Vanda Pharmaceuticals in Q4 2022 and held it in 1 quarter.
Private Trust Company's Vanda Pharmaceuticals position peaked at $0 in Q4 2022.
177 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2023.

Based on Private Trust Company's 13F filing for Q1 2023, filed 12 Apr 2023.